Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation

Table 2

Clinical and demographic features of our six SS patients treated with rituximab.

Pt.

Age*/ sex

Age at SS diagnosis

Age at NHL diagnosis

Anti-SSA/SSB positivity

SS criteria

HCV

RF positivity

Cryo-Ig(pos/type)

CM

Low C4

Persistent parotid swelling

B symptoms

Vasculitis

BM VDJ restriction

Extraglandular manifestations

1

50/F

31

50

SSA/SSB

I, II, III, IV, V, VI

No

No

No

No

No

yes, bilateral

No

No

polyclonal

Arthralgias, fatigue, fibromyalgia

2

59/F

55

59

SSA/SSB

I, II, III, IV, V, VI

No

yes

Type II

IgM-k

yes

yes, bilateral

No

yes

oligoclonal

Neuropathy, ILD, arhralgias, fatigue

3

47/F

41

47

SSA/SSB

I, II, III, V, VI

No

yes

Type II

IgM-k

yes

yes, bilateral

No

yes

polyclonal

Neuropathy, arthralgias, fatigue

4

42/F

41

42

SSA/SSB

I, II, III, V, VI

No

yes

Type II

IgM-k

yes

yes, monolateral

No

No

monoclonal

Thyroiditis, arthralgias, fatigue

5

54/F

46

n.a.

SSA/SSB

I, II, III, IV, V, VI

No

yes

No

No

No

yes, bilateral

No

No

polyclonal

Erosive arthritis, fatigue

6

59/F

57

n.a.

SSA

I, II, III, V, VI

No

yes

Type II

IgM-k

yes

yes, bilateral

No

yes

polyclonal

Raynaud, neuropathy, arthritis, fatigue

Legend: SS: Sjögren’s syndrome; HCV: hepatitis C virus; NHL: non-Hodgkin lymphoma; anti-SSA/SSB: anti-ENA antibodies with SSA/SSB specificity; RF: rheumatoid factor; cryo-Ig: serum crioglobulins; MC: monoclonal component; ILD: interstitial lung disease; BM VDJ: bone marrow variable, diversity and joining region rearrangement; n.a.: not applicable.
*age at RTX therapy.